News coverage about West Pharmaceutical Services (NYSE:WST) has trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. West Pharmaceutical Services earned a news impact score of 0.22 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 46.9456888077791 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

Shares of West Pharmaceutical Services (NYSE:WST) traded up $0.49 during trading hours on Friday, reaching $98.73. 417,937 shares of the company were exchanged, compared to its average volume of 261,889. The company has a market capitalization of $7,331.00, a PE ratio of 42.56, a price-to-earnings-growth ratio of 2.11 and a beta of 1.11. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87. West Pharmaceutical Services has a fifty-two week low of $77.97 and a fifty-two week high of $103.36.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.14. The business had revenue of $398.20 million for the quarter, compared to analysts’ expectations of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the firm posted $0.53 earnings per share. sell-side analysts predict that West Pharmaceutical Services will post 2.76 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on WST shares. Jefferies Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and lifted their price target for the company from $96.00 to $115.00 in a research report on Friday, September 15th. Bank of America downgraded shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target for the company. in a research report on Tuesday, October 17th. Wells Fargo & Company lifted their price target on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Finally, Stephens started coverage on shares of West Pharmaceutical Services in a research report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price target for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services presently has an average rating of “Hold” and a consensus price target of $106.00.

In related news, CFO William J. Federici sold 21,000 shares of West Pharmaceutical Services stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $99.01, for a total value of $2,079,210.00. Following the transaction, the chief financial officer now directly owns 190,493 shares of the company’s stock, valued at $18,860,711.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact West Pharmaceutical Services (WST) Stock Price” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-west-pharmaceutical-services-wst-stock-price.html.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Insider Buying and Selling by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related stocks with our FREE daily email newsletter.